Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Reviva Pharmaceuticals Hldg Inc (RVPH)

Reviva Pharmaceuticals Hldg Inc (RVPH)
0.8700 x 17 0.8900 x 10
Post-market by (Cboe BZX)
0.8627 +0.1027 (+13.51%) 04/23/25 [NASDAQ]
0.8700 x 17 0.8900 x 10
Post-market 0.8900 +0.0273 (+3.16%) 19:44 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.7700
Day High
0.8962
Open 0.7900
Previous Close 0.7600 0.7600
Volume 662,600 662,600
Avg Vol 947,650 947,650
Stochastic %K 77.35% 77.35%
Weighted Alpha -50.78 -50.78
5-Day Change +0.1088 (+14.43%) +0.1088 (+14.43%)
52-Week Range 0.4878 - 4.2800 0.4878 - 4.2800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,522
  • Shares Outstanding, K 46,740
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,920 K
  • EBIT $ -31 M
  • EBITDA $ -31 M
  • 60-Month Beta 0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 42.72
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.91
  • Most Recent Earnings $-0.15 on 03/31/25
  • Next Earnings Date 05/13/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 219.40% ( -50.47%)
  • Historical Volatility 169.99%
  • IV Percentile 62%
  • IV Rank 21.52%
  • IV High 944.78% on 10/03/24
  • IV Low 20.50% on 07/12/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 238
  • Volume Avg (30-Day) 427
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 62,748
  • Open Int (30-Day) 78,822

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.24
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4878 +76.86%
on 04/04/25
Period Open: 1.0400
1.1700 -26.26%
on 03/26/25
-0.1773 (-17.05%)
since 03/21/25
3-Month
0.4878 +76.86%
on 04/04/25
Period Open: 1.8900
2.1500 -59.87%
on 02/06/25
-1.0273 (-54.35%)
since 01/23/25
52-Week
0.4878 +76.86%
on 04/04/25
Period Open: 3.0600
4.2800 -79.84%
on 12/09/24
-2.1973 (-71.81%)
since 04/23/24

Most Recent Stories

More News
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

RVPH : 0.8627 (+13.51%)
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

RVPH : 0.8627 (+13.51%)
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

RVPH : 0.8627 (+13.51%)
Reviva to Participate in the 2025 BIO CEO & Investor Conference

RVPH : 0.8627 (+13.51%)
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

RVPH : 0.8627 (+13.51%)
Reviva Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

Reviva Pharmaceuticals plans to offer common stock and warrants to fund R&D and corporate needs, pending market conditions.Quiver AI SummaryReviva Pharmaceuticals Holdings, Inc. has announced a proposed...

RVPH : 0.8627 (+13.51%)
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

RVPH : 0.8627 (+13.51%)
Reviva Announces Proposed Public Offering

RVPH : 0.8627 (+13.51%)
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

RVPH : 0.8627 (+13.51%)
Reviva Pharmaceuticals Reports Progress on Brilaroxazine Trials and Financial Results for Q3 2024

Reviva Pharmaceuticals reports 108 patients completed a trial for schizophrenia treatment, with topline data expected December 2024.Quiver AI SummaryReviva Pharmaceuticals Holdings, Inc. announced that...

RVPH : 0.8627 (+13.51%)

Business Summary

Reviva Pharmaceuticals Inc. is a clinical stage pharmaceutical company. It engages in developing therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases. The company's lead product candidate includes RP5063, for the treatment...

See More

Key Turning Points

3rd Resistance Point 1.0421
2nd Resistance Point 0.9692
1st Resistance Point 0.9159
Last Price 0.8627
1st Support Level 0.7897
2nd Support Level 0.7168
3rd Support Level 0.6635

See More

52-Week High 4.2800
Fibonacci 61.8% 2.8314
Fibonacci 50% 2.3839
Fibonacci 38.2% 1.9364
Last Price 0.8627
52-Week Low 0.4878

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective